White House Schedules Two More CBD Policy Meetings for April 20 and 21, Bringing Total to Eight
- The White House has scheduled eight total meetings regarding the FDA’s unpublished cannabidiol (CBD) enforcement policy, with two additional sessions on April 20 and 21.
- These meetings involve various stakeholders including advocacy groups like Smart Approaches to Marijuana and industry representatives such as BRC Therapeutics and Groff North America Inc.
- All discussions relate to the FDA’s Cannabidiol (CBD) Products Compliance and Enforcement Policy, which is currently under White House review and has not yet been publicly released.
- The meetings are part of the Office of Information and Regulatory Affairs' federal review process, allowing external input while the policy is being developed and considered.
The White House has scheduled two additional meetings tied to the Food and Drug Administration’s still-unpublished cannabidiol (CBD) enforcement policy, bringing the total number of discussions to eight.
According to the Office of Information and Regulatory Affairs calendar, Smart Approaches to Marijuana is set to meet with officials on April 20 at 2:30 p.m., with Jordan Davidson listed as the requester’s representative. A second meeting has been scheduled for April 21 at 2:30 p.m. with BRC Therapeutics, with George Hodgin listed as the requester’s representative.
Another meeting tied to the same policy is also scheduled for today, April 15 at 3:30 p.m., with Compassion Center & Coalition For Patients Rights, represented by Jason Greninger, as well as April 16 and April 17 with Groff North America Inc. and My TCBD Inc., respectively.
All meetings are connected to the FDA document titled Cannabidiol (CBD) Products Compliance and Enforcement Policy, which remains under White House review at the notice stage.
The newly scheduled sessions follow a series of earlier meetings held on April 1, April 2 and April 7. Those discussions included representatives from Panacea Plant Sciences, Jushi Holdings, Story Cannabis, Iowa hemp farmer Earl Ramey, and OCan Group.
With the addition of the April 20 and April 21 meetings, along with today’s scheduled session, the number of stakeholder discussions tied to the policy has now reached eight, reflecting continued engagement from both industry participants and advocacy groups.
The meetings are part of the federal review process overseen by OIRA, which allows outside stakeholders to provide input while a policy is being considered. The FDA has not yet released the CBD enforcement policy publicly, but it is expected to outline how federal regulators plan to approach compliance for hemp-derived cannabinoid products.